 1. Patients who have had chemotherapy or radiotherapy within 4 weeks 6 weeks for nitrosoureas or mitomycin C prior to entering the study date of consent; or patients who have not recovered from adverse events except grade 1 toxicities due to agents administered more than 4 weeks earlier. 